−0.0157USD
−3.45 MUSD
807.55 KUSD
204.35 M
About Theralase Technologies Inc.
Sector
Industry
CEO
Roger J. Dumoulin-White
Website
Headquarters
Toronto
Founded
1989
FIGI
BBG000LT1796
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. It operates through the Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT) segments. The ACT segment covers the research and development of photo dynamic compounds (PDCs) for the treatment of cancer. The CLT segment is responsible for the company’s medical laser business, which researches, develops, manufactures, and distributes CLT systems to healthcare practitioners predominantly for the healing of pain. The company was founded by Roger J. Dumoulin-White on August 22, 1989 and is headquartered in Toronto, Canada.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TLTFF is 0.1199 USD — it has decreased by 0.42% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Theralase Technologies Inc. stocks are traded under the ticker TLTFF.
Theralase Technologies Inc. is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
TLTFF stock is 1.34% volatile and has beta coefficient of 0.90. Check out the list of the most volatile stocks — is Theralase Technologies Inc. there?
Theralase Technologies Inc. revenue for the last quarter amounts to 206.84 K USD despite the estimated figure of 213.47 K USD. In the next quarter revenue is expected to reach 274.64 K USD.
Yes, you can track Theralase Technologies Inc. financials in yearly and quarterly reports right on TradingView.
TLTFF stock has fallen by 8.51% compared to the previous week, the month change is a 7.05% fall, over the last year Theralase Technologies Inc. has showed a 40.29% decrease.
TLTFF net income for the last quarter is −747.73 K USD, while the quarter before that showed −747.63 K USD of net income which accounts for −0.01% change. Track more Theralase Technologies Inc. financial stats to get the full picture.
Today Theralase Technologies Inc. has the market capitalization of 26.65 M, it has increased by 2.07% over the last week.
No, TLTFF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TLTFF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Theralase Technologies Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Theralase Technologies Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Theralase Technologies Inc. stock shows the strong sell signal. See more of Theralase Technologies Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Theralase Technologies Inc. future price: according to them, TLTFF price has a max estimate of 0.60 USD and a min estimate of 0.60 USD. Read a more detailed Theralase Technologies Inc. forecast: see what analysts think of Theralase Technologies Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Theralase Technologies Inc. EBITDA is −3.25 M USD, and current EBITDA margin is −402.51%. See more stats in Theralase Technologies Inc. financial statements.